| Name | Title | Contact Details |
|---|
For more than 130 years, Carstens has focused on the specific and evolving needs of healthcare professionals - providing revolutionary solutions that transform clinical environments, enhance patient experiences and positively impact results. The first to bring patient information to the point of care, we have always been passionate about connecting with the human side of healthcare. Today, we continue to lead the industry with our inventive product development - bringing new solutions to new demands for more efficient, productive and interactive care. Carstens - connecting with the human side of healthcare.
Bach Mobilities Inc is a Escanaba, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nightengale Home Healthcare Inc is a Carmel, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
Since 1987, Valley Behavioral Health has provided comprehensive treatment and services for people of all ages who are experiencing serious mental illness, substance use disorders and behavior problems. We believe people are best served in the least restrictive setting where care is tailored to the individual's needs. Families and community partners play an important role in a person's recovery.